MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
13.26
+0.29
+2.20%
Opening 13:07 05/21 EDT
OPEN
12.94
PREV CLOSE
12.97
HIGH
13.47
LOW
12.45
VOLUME
80.43K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
3.240
MARKET CAP
151.46M
P/E (TTM)
-2.1848
1D
5D
1M
3M
1Y
5Y
1D
Kazia Therapeutics files beneficial ownership statement for Chief Scientific Officer Sudha Rao
PUBT · 2d ago
Weekly Report: what happened at KZIA last week (0511-0515)?
Weekly Report · 3d ago
Weekly Report: what happened at KZIA last week (0504-0508)?
Weekly Report · 05/11 09:08
Weekly Report: what happened at KZIA last week (0427-0501)?
Weekly Report · 05/04 09:08
Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst
Seeking Alpha · 04/29 13:04
Kazia Therapeutics Limited - Depositary Receipt (KZIA) Price Target Increased by 10.53% to 21.42
NASDAQ · 04/28 03:29
Kazia Therapeutics publishes corporate overview outlining oncology pipeline and development plans
PUBT · 04/28 00:57
Kazia Therapeutics Unveils April 2026 Investor Update Showcasing Multi-Modal Oncology Pipeline
TipRanks · 04/27 12:54
More
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Webull offers Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ: KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.